BioCardia, Inc. (BCDA) community

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83+0.01 (+0.61%)

Close on Nov 13, 2026Market cap $12.58MP/E –Yield –

Community

Notes and questions about BioCardia from other investors

No posts about BCDA yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in BioCardia's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on May 30, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCDA.

Compare: BCDA vs CELZ · BCDA vs ALLO · BCDA vs SNTI · BCDA vs TLPH · BCDA vs TCRT

Revenue growth-100.0% · median -50.0%

Company	Revenue	Growth
CELZ	$3.00K	-50.0%
TCRT	$3.00K	-50.0%
BCDA	$0	-100.0%
ALLO	–	–
SNTI	–	–
TLPH	$0	-100.0%

Company

Next earnings (est.): Mar 23, 2027, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 21
Held by institutions: 8.8%
Auditor: PKF San Diego, LLP
SEC CIK: 925741

Advertisement
300 × 250

See a number that looks wrong?